Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction
Status:
Completed
Trial end date:
2021-04-19
Target enrollment:
Participant gender:
Summary
Patients with ST-segment elevation myocardial infarction (STEMI) that have suffered a major
anterior wall infarction or where coronary blood flow is less than normal in spite of
successful percutaneous coronary intervention (PCI) have a poor prognosis. There are today no
medical treatments that specifically reduce risk in these patients. The acute inflammatory
reaction in conjunction with a STEMI and reperfusion by PCI determines the final size of the
infarction and the signals leading to left ventricular remodelling.
This study is designed to assess the efficacy and safety of single intravenous injection with
ATH3G10, a fully human IgG1 antibody against phosphorylcholine, in high-risk subjects with
STEMI. ATH3G10 aims to reduce inflammation and thereby infarction size and remodeling.